{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,6]],"date-time":"2026-03-06T13:30:28Z","timestamp":1772803828984,"version":"3.50.1"},"reference-count":28,"publisher":"Springer Science and Business Media LLC","issue":"13","license":[{"start":{"date-parts":[[2023,8,23]],"date-time":"2023-08-23T00:00:00Z","timestamp":1692748800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2023,8,23]],"date-time":"2023-08-23T00:00:00Z","timestamp":1692748800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Ann Surg Oncol"],"published-print":{"date-parts":[[2023,12]]},"DOI":"10.1245\/s10434-023-14029-7","type":"journal-article","created":{"date-parts":[[2023,8,23]],"date-time":"2023-08-23T13:02:41Z","timestamp":1692795761000},"page":"8371-8380","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":5,"title":["Surgical Management of the Axilla in HR+\/HER2\u2013 Breast Cancer in the Z1071 Era: A Propensity Score-Matched Analysis of the National Cancer Database"],"prefix":"10.1245","volume":"30","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-4452-8926","authenticated-orcid":false,"given":"Vayda R.","family":"Barker","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Samer A.","family":"Naffouje","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Melissa A.","family":"Mallory","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Susan A.","family":"Hoover","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Christine","family":"Laronga","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2023,8,23]]},"reference":[{"key":"14029_CR1","doi-asserted-by":"publisher","first-page":"438","DOI":"10.3322\/caac.21583","volume":"69","author":"CE DeSantis","year":"2019","unstructured":"DeSantis CE, Ma J, Gaudet MM, et al. Breast cancer statistics, 2019. CA Cancer J Clin. 2019;69:438\u201351.","journal-title":"CA Cancer J Clin."},{"key":"14029_CR2","doi-asserted-by":"publisher","first-page":"e12965","DOI":"10.1097\/MD.0000000000012965","volume":"97","author":"JM Dong","year":"2018","unstructured":"Dong JM, Wang HX, Zhong XF, et al. Changes in background parenchymal enhancement in HER2-positive breast cancer before and after neoadjuvant chemotherapy: association with pathologic complete response. Med Baltimore. 2018;97:e12965.","journal-title":"Med Baltimore."},{"key":"14029_CR3","doi-asserted-by":"publisher","first-page":"34","DOI":"10.4132\/jptm.2019.11.03","volume":"54","author":"S Ahn","year":"2020","unstructured":"Ahn S, Woo JW, Lee K, Park SY. HER2 status in breast cancer: changes in guidelines and complicating factors for interpretation. J Pathol Transl Med. 2020;54:34\u201344.","journal-title":"J Pathol Transl Med."},{"key":"14029_CR4","doi-asserted-by":"publisher","first-page":"619","DOI":"10.1158\/1055-9965.EPI-17-0627","volume":"27","author":"N Howlader","year":"2018","unstructured":"Howlader N, Cronin KA, Kurian AW, Andridge R. Differences in breast cancer survival by molecular subtypes in the United States. Cancer Epidemiol Biomarkers Prev. 2018;27:619\u201326.","journal-title":"Cancer Epidemiol Biomarkers Prev."},{"key":"14029_CR5","doi-asserted-by":"publisher","first-page":"136","DOI":"10.1038\/bjc.1992.230","volume":"66","author":"D Ivens","year":"1992","unstructured":"Ivens D, Hoe AL, Podd TJ, Hamilton CR, Taylor I, Royle GT. Assessment of morbidity from complete axillary dissection. Br J Cancer. 1992;66:136\u20138.","journal-title":"Br J Cancer."},{"key":"14029_CR6","doi-asserted-by":"publisher","first-page":"546","DOI":"10.1056\/NEJMoa012782","volume":"349","author":"U Veronesi","year":"2003","unstructured":"Veronesi U, Paganelli G, Viale G, et al. A randomized comparison of sentinel-node biopsy with routine axillary dissection in breast cancer. N Engl J Med. 2003;349:546\u201353.","journal-title":"N Engl J Med."},{"key":"14029_CR7","doi-asserted-by":"publisher","first-page":"1455","DOI":"10.1001\/jama.2013.278932","volume":"310","author":"JC Boughey","year":"2013","unstructured":"Boughey JC, Suman VJ, Mittendorf EA, et al. Sentinel lymph node surgery after neoadjuvant chemotherapy in patients with node-positive breast cancer: the ACOSOG Z1071 (Alliance) clinical trial. JAMA. 2013;310:1455\u201361.","journal-title":"JAMA."},{"key":"14029_CR8","doi-asserted-by":"publisher","first-page":"258","DOI":"10.1200\/JCO.2014.55.7827","volume":"33","author":"JF Boileau","year":"2015","unstructured":"Boileau JF, Poirier B, Basik M, et al. Sentinel node biopsy after neoadjuvant chemotherapy in biopsy-proven node-positive breast cancer: the SN FNAC study. J Clin Oncol. 2015;33:258\u201364.","journal-title":"J Clin Oncol."},{"key":"14029_CR9","doi-asserted-by":"publisher","first-page":"609","DOI":"10.1016\/S1470-2045(13)70166-9","volume":"14","author":"T Kuehn","year":"2013","unstructured":"Kuehn T, Bauerfeind I, Fehm T, et al. Sentinel lymph node biopsy in patients with breast cancer before and after neoadjuvant chemotherapy (SENTINA): a prospective, multicentre cohort study. Lancet Oncol. 2013;14:609\u201318.","journal-title":"Lancet Oncol."},{"key":"14029_CR10","first-page":"3611","volume":"11","author":"M Oshi","year":"2021","unstructured":"Oshi M, Gandhi S, Angarita FA, et al. A novel five-gene score to predict complete pathological response to neoadjuvant chemotherapy in ER-positive\/HER2-negative breast cancer. Am J Cancer Res. 2021;11:3611\u201327.","journal-title":"Am J Cancer Res."},{"key":"14029_CR11","doi-asserted-by":"publisher","first-page":"1049","DOI":"10.1200\/JCO.2015.63.1010","volume":"35","author":"WF Symmans","year":"2017","unstructured":"Symmans WF, Wei C, Gould R, et al. Long-term prognostic risk after neoadjuvant chemotherapy associated with residual cancer burden and breast cancer subtype. J Clin Oncol. 2017;35:1049\u201360.","journal-title":"J Clin Oncol."},{"key":"14029_CR12","doi-asserted-by":"publisher","first-page":"608","DOI":"10.1097\/SLA.0000000000000924","volume":"260","author":"JC Boughey","year":"2014","unstructured":"Boughey JC, McCall LM, Ballman KV, et al. Tumor biology correlates with rates of breast-conserving surgery and pathologic complete response after neoadjuvant chemotherapy for breast cancer: findings from the ACOSOG Z1071 (Alliance) prospective multicenter clinical trial. Ann Surg. 2014;260:608\u201316 (Discussion 614\u2013606).","journal-title":"Ann Surg."},{"key":"14029_CR13","doi-asserted-by":"publisher","first-page":"1404","DOI":"10.3390\/cancers12061404","volume":"12","author":"JS Lee","year":"2020","unstructured":"Lee JS, Yost SE, Yuan Y. Neoadjuvant treatment for triple-negative breast cancer: recent progresses and challenges. Cancers Basel. 2020;12:1404.","journal-title":"Cancers Basel."},{"key":"14029_CR14","doi-asserted-by":"publisher","first-page":"34","DOI":"10.1200\/EDBK_159135","volume":"35","author":"CK Anders","year":"2016","unstructured":"Anders CK, Abramson V, Tan T, Dent R. The evolution of triple-negative breast cancer: from biology to novel therapeutics. Am Soc Clin Oncol Educ Book. 2016;35:34\u201342.","journal-title":"Am Soc Clin Oncol Educ Book."},{"key":"14029_CR15","doi-asserted-by":"publisher","first-page":"103280","DOI":"10.1016\/j.critrevonc.2021.103280","volume":"160","author":"R Torrisi","year":"2021","unstructured":"Torrisi R, Marrazzo E, Agostinetto E, et al. Neoadjuvant chemotherapy in hormone receptor-positive\/HER2-negative early breast cancer: when, why, and what? Crit Rev Oncol Hematol. 2021;160:103280.","journal-title":"Crit Rev Oncol Hematol."},{"key":"14029_CR16","doi-asserted-by":"publisher","first-page":"927","DOI":"10.1016\/S1470-2045(10)70207-2","volume":"11","author":"DN Krag","year":"2010","unstructured":"Krag DN, Anderson SJ, Julian TB, et al. Sentinel lymph node resection compared with conventional axillary lymph node dissection in clinically node-negative patients with breast cancer: overall survival findings from the NSABP B-32 randomised phase 3 trial. Lancet Oncol. 2010;11:927\u201333.","journal-title":"Lancet Oncol."},{"key":"14029_CR17","doi-asserted-by":"publisher","first-page":"569","DOI":"10.1001\/jama.2011.90","volume":"305","author":"AE Giuliano","year":"2011","unstructured":"Giuliano AE, Hunt KK, Ballman KV, et al. Axillary dissection vs no axillary dissection in women with invasive breast cancer and sentinel node metastasis: a randomized clinical trial. JAMA. 2011;305:569\u201375.","journal-title":"JAMA."},{"key":"14029_CR18","doi-asserted-by":"publisher","first-page":"297","DOI":"10.1016\/S1470-2045(13)70035-4","volume":"14","author":"V Galimberti","year":"2013","unstructured":"Galimberti V, Cole BF, Zurrida S, et al. Axillary dissection versus no axillary dissection in patients with sentinel-node micrometastases (IBCSG 23\u201301): a phase 3 randomised controlled trial. Lancet Oncol. 2013;14:297\u2013305.","journal-title":"Lancet Oncol."},{"key":"14029_CR19","unstructured":"National Comprehensive Cancer Network. Breast Cancer (version 2.2022). Retrieved 4 January 2022 at https:\/\/www.nccn.org\/guidelines\/guidelines-detail?category=1&id=1419."},{"key":"14029_CR20","doi-asserted-by":"publisher","first-page":"8777","DOI":"10.1245\/s10434-021-10411-5","volume":"28","author":"SA Naffouje","year":"2021","unstructured":"Naffouje SA, Sabesan A, Hoover SJ, Lee MC, Laronga C. Surgical management of the axilla of HER2+ breast cancer in the Z1071 era: a propensity score-matched analysis of the NCDB. Ann Surg Oncol. 2021;28:8777\u201388.","journal-title":"Ann Surg Oncol."},{"key":"14029_CR21","doi-asserted-by":"publisher","first-page":"2985","DOI":"10.1245\/s10434-021-11194-5","volume":"29","author":"SA Naffouje","year":"2022","unstructured":"Naffouje SA, Barker V, Lee MC, Hoover SJ, Laronga C. Surgical management of axilla of triple-negative breast cancer in the Z1071 era: a propensity score-matched analysis of the National Cancer Database. Ann Surg Oncol. 2022;29:2985\u201397.","journal-title":"Ann Surg Oncol."},{"key":"14029_CR22","first-page":"541","volume":"26","author":"RD Rao","year":"2012","unstructured":"Rao RD, Cobleigh MA. Adjuvant endocrine therapy for breast cancer. Oncology Williston Park. 2012;26:541\u20137 (550, 552 passim).","journal-title":"Oncology Williston Park."},{"key":"14029_CR23","doi-asserted-by":"publisher","first-page":"927","DOI":"10.1200\/JCO.2015.62.3504","volume":"34","author":"M Colleoni","year":"2016","unstructured":"Colleoni M, Sun Z, Price KN, et al. Annual hazard rates of recurrence for breast cancer during 24 years of follow-up: results from the International Breast Cancer Study Group trials I to V. J Clin Oncol. 2016;34:927\u201335.","journal-title":"J Clin Oncol."},{"key":"14029_CR24","doi-asserted-by":"publisher","first-page":"1303","DOI":"10.1016\/S1470-2045(14)70460-7","volume":"15","author":"M Donker","year":"2014","unstructured":"Donker M, van Tienhoven G, Straver ME, et al. Radiotherapy or surgery of the axilla after a positive sentinel node in breast cancer (EORTC 10981\u201322023 AMAROS): a randomised, multicentre, open-label, phase 3 non-inferiority trial. Lancet Oncol. 2014;15:1303\u201310.","journal-title":"Lancet Oncol."},{"key":"14029_CR25","doi-asserted-by":"publisher","first-page":"918","DOI":"10.1001\/jama.2017.11470","volume":"318","author":"AE Giuliano","year":"2017","unstructured":"Giuliano AE, Ballman KV, McCall L, et al. Effect of axillary dissection vs no axillary dissection on 10-year overall survival among women with invasive breast cancer and sentinel node metastasis: the ACOSOG Z0011 (Alliance) randomized clinical trial. JAMA. 2017;318:918\u201326.","journal-title":"JAMA."},{"key":"14029_CR26","doi-asserted-by":"publisher","first-page":"3467","DOI":"10.1245\/s10434-016-5246-8","volume":"23","author":"A Mamtani","year":"2016","unstructured":"Mamtani A, Barrio AV, King TA, et al. How often does neoadjuvant chemotherapy avoid axillary dissection in patients with histologically confirmed nodal metastases? Results of a prospective study. Ann Surg Oncol. 2016;23:3467\u201374.","journal-title":"Ann Surg Oncol."},{"key":"14029_CR27","doi-asserted-by":"publisher","first-page":"2838","DOI":"10.1158\/1078-0432.CCR-19-3492","volume":"26","author":"LM Spring","year":"2020","unstructured":"Spring LM, Fell G, Arfe A, et al. Pathologic complete response after neoadjuvant chemotherapy and impact on breast cancer recurrence and survival: a comprehensive meta-analysis. Clin Cancer Res. 2020;26:2838\u201348.","journal-title":"Clin Cancer Res."},{"key":"14029_CR28","doi-asserted-by":"publisher","first-page":"1796","DOI":"10.1200\/JCO.2011.38.8595","volume":"30","author":"G von Minckwitz","year":"2012","unstructured":"von Minckwitz G, Untch M, Blohmer JU, et al. Definition and impact of pathologic complete response on prognosis after neoadjuvant chemotherapy in various intrinsic breast cancer subtypes. J Clin Oncol. 2012;30:1796\u2013804.","journal-title":"J Clin Oncol."}],"container-title":["Annals of Surgical Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1245\/s10434-023-14029-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1245\/s10434-023-14029-7\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1245\/s10434-023-14029-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,11,5]],"date-time":"2023-11-05T15:05:42Z","timestamp":1699196742000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1245\/s10434-023-14029-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,8,23]]},"references-count":28,"journal-issue":{"issue":"13","published-print":{"date-parts":[[2023,12]]}},"alternative-id":["14029"],"URL":"https:\/\/doi.org\/10.1245\/s10434-023-14029-7","relation":{},"ISSN":["1068-9265","1534-4681"],"issn-type":[{"value":"1068-9265","type":"print"},{"value":"1534-4681","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,8,23]]},"assertion":[{"value":"8 April 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 July 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 August 2023","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"There are no conflicts of interest.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Disclosure"}}]}}